CGEN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Compugen Ltd (CGEN) does not present a strong buy opportunity for a beginner investor with a long-term horizon and $50,000-$100,000 available for investment. While the stock has shown a bullish technical setup and has a promising analyst rating with a $6 price target, the lack of recent news, insider selling trends, and mixed financial performance (revenue growth but significant net income and EPS declines) suggest caution. Additionally, no strong trading signals or congress trading data are available to support a buy decision.
The technical indicators suggest a bullish trend with SMA_5 > SMA_20 > SMA_200 and a MACD histogram above 0. However, RSI is in the neutral zone, and the stock is trading near its resistance level (R1: 2.965). The stock's recent price movements indicate limited upside in the short term.
Analyst Chad Messer initiated coverage with a Buy rating and a $6 price target, citing Compugen's unique TIGIT design and partnership with AstraZeneca.
Revenue increased significantly (4477.29% YoY) in Q4 2025, showing potential for growth.
Insiders have been selling shares, with a 177.02% increase in selling activity over the last month.
Net income and EPS have declined sharply (-1029.30% and -942.86% YoY, respectively).
No recent news or congress trading data to act as a catalyst.
In Q4 2025, revenue increased significantly by 4477.29% YoY, and gross margin improved to 94.75%. However, net income dropped by -1029.30%, and EPS fell by -942.86%, indicating profitability challenges.
Lake Street analyst Chad Messer initiated coverage with a Buy rating and a $6 price target, highlighting the company's innovative TIGIT design and collaboration with AstraZeneca. However, no other recent analyst updates or price target changes are available.
